Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRB | P23467 | 1/20 | 0.54 |
| ▸ | PPARG | P37231 | 9/20 | 0.48 |
| ▸ | PPARD | Q03181 | 5/20 | 0.48 |
| ▸ | PPARA | Q07869 | 4/20 | 0.48 |
| ▸ | LDHA | P00338 | 2/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | MIF | P14174 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | ANPEP | P15144 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5872055 | 0.84 | MMP8 (0.54) | PTPRBLDHAMMP8ALDH1A1 | |
| SCHEMBL1442737 | 0.81 | MMP8 (0.58) | PTPRBPPARGPPARDPPARALDHA | |
| SCHEMBL5872172 | 0.81 | MMP8 (0.41) | PTPRBPPARGPPARDPPARALDHA | |
| SCHEMBL5872049 | 0.80 | PTPRB (0.49) | PTPRBPPARGPPARDPPARAMMP8 | |
| SCHEMBL16327191 | 0.79 | PTPRB (0.59) | PTPRBPPARGPPARDPPARALDHA | |
| SCHEMBL6380182 | 0.79 | ESR1 (0.67) | PTPRBPPARGPPARDPPARALDHA | |
| SCHEMBL6027407 | 0.79 | LDHA (0.40) | PTPRBLDHAESR1ESR2MMP8 | |
| SCHEMBL5871668 | 0.78 | TSHR (0.42) | PPARGPPARDPPARALDHAESR1 | |
| SCHEMBL5872159 | 0.78 | PTPRB (0.44) | PTPRBPPARGPPARDPPARALDHA | |
| SCHEMBL5871568 | 0.78 | PTPRB (0.44) | PTPRBPPARGPPARDPPARALDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7071187-B2 | Naphthyridine derivatives | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2006-07-04 | — | — | US | disclosed |
| US-20040214853-A1 | Naphthyridine derivatives | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2004-10-28 | — | — | US | disclosed |
| EP-1426374-A1 | NAPHTHYRIDINE DERIVATIVE | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2004-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214853-A1 | Naphthyridine derivatives | MT-ND1, OPRD1, NR0B1 | PTPRB 3070/4885PPARG 1417/4885PPARD 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.